Z-0641-2024 Class II Ongoing

Recalled by Becton, Dickinson And Company, BD Biosciences — San Jose, CA

FDA device recall Z-0641-2024 was initiated by Becton, Dickinson And Company, BD Biosciences on Oct 25, 2023 and is designated Class II. Reason for recall: In vitro diagnostics product that impacts the quality of cell staining can cause low or dim fluorescence signal, which can lead to potential false negative results and misdiagnosis of hematological… The recall status is ongoing. Affected quantity: 464 Vials.

Recall details

Product Type
Devices
Report Date
Jan 17, 2024
Initiation Date
Oct 25, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
464 Vials

Product description

CD11b APC: ASR, REF: 340936, and CE, REF: 333143

Reason for recall

In vitro diagnostics product that impacts the quality of cell staining can cause low or dim fluorescence signal, which can lead to potential false negative results and misdiagnosis of hematological malignancy, delayed treatment, and the need for additional patient samples.

Distribution pattern

Worldwide - US Nationwide distribution including in the states of IL, MN, FL, MI, MD, NC, NY, CA, GA, AR, KS, PA, NH, TX, OK, MA, MO, DC, AZ, IN, NJ, TN, WA, VA, CT and the countries of CA, BE, SG, HK, TW, BR, MY, IN, BO, PE, JP, MX, CL, KR, UY, AU.

Code information

REF/UDI-DI/Expiration: 340936/00382903409365/20250228; 333143/00382903331437/20250228

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-0641-2024
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-0641-2024. Report a data issue: hello@regdatalab.com.